Androgen receptor signaling inhibitor (ARSI)

DRUG2 trials

Sponsors

Astellas Pharma Global Development, Inc., Case Comprehensive Cancer Center

Conditions

Hormone-refractory Prostate CancerMalignant Neoplasm of ProstateProstate CancerSecondary Malignant Neoplasm of Prostate

Phase 1

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

RecruitingNCT05997615

Astellas Pharma Global Development, Inc.Hormone-refractory Prostate Cancer

Start: 2023-08-10End: 2027-09-29Target: 437Updated: 2026-09-10

Phase 2

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

RecruitingNCT06150417

Case Comprehensive Cancer CenterMalignant Neoplasm of Prostate, Prostate Cancer, Secondary Malignant Neoplasm of Prostate

Start: 2024-07-01End: 2028-12-01Target: 200Updated: 2026-09-15

Related Papers

METANOVA: A phase II trial of metastasis-directed radiotherapy for de novo oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial.

Journal of Clinical Oncology2025-05-28